CervoMed’s neflamapimod shows efficacy in slowing dementia

Cervomed (CRVO) announced that, in a late-breaking oral session at the 18th Clinical Trials on Alzheimer’s Disease Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by CervoMed for the treatment of dementia with Lewy bodies, or DLB. In the trial, neflamapimod demonstrated a significant and clinically meaningful effect on multiple outcomes in DLB patients, including on the primary outcome measure, change in CDR sum-of-boxes. These positive clinical outcomes were correlated with observed reductions in glial fibrillary acidic protein, a biomarker of neuronal damage, supporting neflamapimod’s mode of action targeting the underlying mechanism of DLB. A significant improvement on the primary endpoint, CDR-SB, at week 16 of the extension phase, with a mean change that was 52% lower with DP Batch B compared to DP Batch A in all participants and 82% lower in patients. The clinical effect in CDR-SB was durable to 32 weeks, with a 65% reduction in clinical worsening in all participants and an 89% reduction in clinical worsening in the less than21.0 pg/mL ptau181 subgroup. In addition, neflamapimod was well-tolerated with a low rate of treatment discontinuation over 48 weeks of treatment during the trial.